Pamela Crilley, DO
Hematology & Oncology · Pennington, NJNPI 1538116041
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 10.5% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for hematology & oncology clinicians in NJ, where the typical reported total is $2,686.
Across 126 payments — averaging $21.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$283
- Sanofi$252
- Novartis$237
- Sobi, Inc$224
- AstraZeneca$213
- AbbVie$179
- plus $1K from 33 others
Across 52 payments — averaging $18,049 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$925K
- Aptevo Therapeutics Inc$13K
- Genentech, Inc.$390
What the payments were for
- Food & beverage$2,44491%
- Education$2429%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 16 | $283 |
| Sanofi | 12 | $252 |
| Novartis | 11 | $237 |
| Sobi, Inc | 8 | $224 |
| AstraZeneca(2 entities) | 12 | $213 |
| AbbVie | 5 | $179 |
| Gilead | 5 | $146 |
| Seagen Inc. | 1 | $119 |
| E.r. Squibb & Sons, L.L.C. | 5 | $91 |
| GSK | 5 | $88 |
| Johnson & Johnson | 3 | $65 |
| Lilly USA, LLC | 4 | $57 |
| Incyte Corporation | 3 | $53 |
| Sumitomo Pharma America, Inc. | 3 | $50 |
| Pfizer | 3 | $47 |
| Stemline Therapeutics Inc. | 2 | $47 |
| Array Biopharma Inc | 2 | $44 |
| Beone Medicines USA, Inc. | 2 | $40 |
| Merck | 2 | $37 |
| Astellas Pharma US Inc | 2 | $37 |
| Pharmacosmos Therapeutics Inc. | 2 | $35 |
| AVEO Pharmaceuticals, Inc. | 1 | $28 |
| Adaptive Biotechnologies Corporation | 1 | $25 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Myovant Sciences Inc. | 1 | $20 |
| Baxter Healthcare | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Genentech USA, Inc. | 1 | $19 |
| Novocure Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Genmab U.S., Inc. | 1 | $18 |
| Apellis Pharmaceuticals, Inc. | 1 | $18 |
| Servier Pharmaceuticals LLC | 1 | $18 |
| Taiho Oncology, Inc. | 1 | $17 |
| Geron Corporation | 1 | $17 |
| Beigene USA, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Bayer | 1 | $16 |
| EMD Serono, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,686 in reported general payments places this provider in the 50th percentile of 362 hematology & oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 75 | $692,214 |
| RevlimidLenalidomide | 20 | $468,730 |
| IbrancePalbociclib | 20 | $307,614 |
| XtandiEnzalutamide | 12 | $165,974 |
| VerzenioAbemaciclib | 11 | $163,295 |
| EliquisApixaban | 90 | $74,737 |
| XareltoRivaroxaban | 11 | $9,123 |
| Anastrozole | 225 | $7,552 |
| Imatinib Mesylate | 19 | $4,302 |
| Letrozole | 59 | $2,297 |
| Acyclovir | 70 | $910 |
| Dexamethasone | 25 | $605 |
| Ondansetron OdtOndansetron | 18 | $376 |
| Allopurinol | 44 | $349 |
| Oxycodone Hcl | 14 | $333 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $213 | $692,21475 claims |
| PfizerIbrance, Eliquis | $47 | $382,351110 claims |
| Astellas Pharma US IncXtandi | $37 | $165,97412 claims |
| Lilly USA, LLCVerzenio | $57 | $163,29511 claims |
| Johnson & JohnsonXarelto | $65 | $9,12311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 362 hematology & oncology providers in New Jersey.
Other hematology & oncology in Pennington
- Arturo Loaiza-BonillaPennington$406K
- Robert SpiegelWestfield$864K
- Amit PatelJersey City$770K
- Joshua StraussSpringfield$739K
- Charles FarberMorristown$609K
- Michael ScolaMorristown$506K
- Eshan PatelSomerville$420K
- Ashish ShahSpringfield$394K
- Carl HenningsonManasquan$349K
- Anthony BottiLivingston$275K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.